Prescient Therapeutics: PTX-100 targeted cell therapy briefing
Prescient Therapeutics: PTX-100 targeted cell therapy briefing Prescient Therapeutics CEO and MD Steven Yatomi-Clarke gave...
Prescient Therapeutics: PTX-100 targeted cell therapy briefing Prescient Therapeutics CEO and MD Steven Yatomi-Clarke gave...
Prescient was pleased to present data on our cell therapies at the prestigious International Society...
Prescient Therapeutics: Cell Therapies presentations from ISCT Prescient Therapeutics held a special Cell Therapies briefing...
Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke presented at the...
Prescient Therapeutics Shareholder Briefing In this session, Prescient Therapeutics CEO and MD Steven Yatomi-Clarke discussed:...
Prescient Therapeutics: PTX-100 targeted cell therapy briefing Prescient Therapeutics CEO and MD Steven Yatomi-Clarke gave...
Clinical stage oncology company, Prescient Therapeutics, has a diverse stable of emerging and later stage...
Prescient Therapeutics Shareholder Briefing In this session, Prescient Therapeutics CEO and MD Steven Yatomi-Clarke discussed:...
Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke presented at the...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.